Source:http://linkedlifedata.com/resource/pubmed/id/20181652
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2010-3-26
|
pubmed:abstractText |
NKT cells are characterized by their production of both T(h)1 and T(h)2 cytokines immediately after stimulation with alpha-galactosylceramide (alpha-GalCer), which is composed of alpha-galactopyranose linked to ceramide (itself composed of sphingosine and fatty-acyl chains); the chain length of the ceramide varies and this affects the ability of alpha-GalCer to stimulate cytokine production. However, the contribution of its galactopyranose sugar moiety remains unclear. We synthesized alpha-carba-GalCer, which has an alpha-linked carba-galactosyl moiety; here, the 5a'-oxygen atom of the D-galactopyranose ring of alpha-GalCer is replaced by a methylene group. The alpha-carba-GalCer was more stable and showed higher affinity to the NKT receptor. It thus enhanced and prolonged production of IL-12 and IFN-gamma compared with alpha-GalCer, resulting in augmented NKT cell-mediated adjuvant effects in vivo. The alpha-carba-GalCer, which has an ether linkage, was more resistant to degradation by liver microsomes than was alpha-GalCer, which has an acetal bond. Modulation of the sugar moiety in glycolipids might therefore provide optimal therapeutic reagents for protective immune responses against tumor or pathogens.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclohexanols,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Galactosylceramides,
http://linkedlifedata.com/resource/pubmed/chemical/Glycolipids,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1460-2377
|
pubmed:author |
pubmed-author:ChibaTomokiT,
pubmed-author:FujiiShin-IchiroS,
pubmed-author:HongoNaomiN,
pubmed-author:InoueSayoS,
pubmed-author:MoriKenjiK,
pubmed-author:NakagawaRyusukeR,
pubmed-author:Omori-MiyakeMiyukiM,
pubmed-author:Sekine-KondoEtsukoE,
pubmed-author:ShigeuraTomokuniT,
pubmed-author:ShimizuKanakoK,
pubmed-author:SumidaTakayukiT,
pubmed-author:TaniguchiMasaruM,
pubmed-author:TashiroTakuyaT,
pubmed-author:WataraiHiroshiH,
pubmed-author:YoshigaYoheiY
|
pubmed:issnType |
Electronic
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
319-28
|
pubmed:meshHeading |
pubmed-meshheading:20181652-Adjuvants, Immunologic,
pubmed-meshheading:20181652-Animals,
pubmed-meshheading:20181652-Cell Line,
pubmed-meshheading:20181652-Cyclohexanols,
pubmed-meshheading:20181652-Cytokines,
pubmed-meshheading:20181652-Galactosylceramides,
pubmed-meshheading:20181652-Glycolipids,
pubmed-meshheading:20181652-Humans,
pubmed-meshheading:20181652-Injections, Intravenous,
pubmed-meshheading:20181652-Ligands,
pubmed-meshheading:20181652-Mice,
pubmed-meshheading:20181652-Natural Killer T-Cells,
pubmed-meshheading:20181652-Th1 Cells
|
pubmed:year |
2010
|
pubmed:articleTitle |
Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells.
|
pubmed:affiliation |
Laboratory for Immune Regulation, RIKEN Research Center for Allergy and Immunology, Tsurumi, Yokohama, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|